Impact of initiation of SGLT2 inhibitor treatment on the development of arrhythmias in patients with implantable cardiac devices.
SGLT2 抑制劑治療開始對植入式心臟裝置患者心律失常發展的影響。
Rev Esp Cardiol (Engl Ed) 2024-02-03
Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials.
二型糖尿病患者中與心律不整有關的鈉葡萄糖共同轉運蛋白2抑制劑:隨機安慰劑對照試驗的系統性回顧和荟萃分析。
Clin Res Cardiol 2024-02-14
Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i-Arrhythmias and Sudden Cardiac Death).
SGLT-2抑制劑對心律失常事件的影響:從超過80,000名患者的更新次級分析中獲得的見解(SGLT2i-心律失常和猝死)。
Cardiovasc Diabetol 2024-03-13
Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial.
empagliflozin對植入式心臟除顫器治療的2型糖尿病患者心室心律失常的影響:EMPA-ICD試驗。
Cardiovasc Diabetol 2024-06-29
The effects of empagliflozin on ventricular arrhythmias in heart failure patients with an implantable cardioverter-defibrillator: a double-blind randomized controlled trial.
Empagliflozin對植入式心臟除顫器心衰患者心室心律失常的影響:一項雙盲隨機對照試驗。
Naunyn Schmiedebergs Arch Pharmacol 2024-07-13
Examining the Impact of Ertugliflozin on Cardiovascular Outcomes in Patients with Diabetes and Metabolic Syndrome: A Systematic Review of Clinical Trials.
檢視Ertugliflozin對糖尿病及代謝症候群患者心血管結果的影響:一項臨床試驗的系統性回顧。
Pharmaceuticals (Basel) 2024-07-27
Association of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) with Cardiac Arrhythmias: A Systematic Review and Meta-Analysis of Cardiovascular Outcome Trials.
鈉-葡萄糖共轉運蛋白 2 抑制劑 (SGLT2i) 與心臟心律不整的關聯:心血管結果試驗的系統性回顧與統合分析。
Rev Cardiovasc Med 2024-07-30